Press release
Monopar to Present at the Jefferies Radiopharma Innovation Summit
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing
About this update from Monopar Therapeutics Inc.
[{"type":"text","content":"WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week. Presentation Details: Date: April 3, 2023Time: 1:00 – 1:30 pm Location: Jefferies Conference Center, NYC, New York About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com. CONTACT: Monopar Therapeutics Inc. Investor RelationsKim R. TsuchimotoChief Financial [email protected] Follow Monopar on social media for updates: Twitter: @MonoparTx LinkedIn: Monopar Therapeutics \nSource: Monopar Therapeutics Inc.","length":4076,"tagName":"div"}]